Clinical Trial Update: A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing the safety and ability of Andexanet Alfa to reverse apixaban anticoagulation in older subjects; study completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bleeding Disorders

Drugs mentioned

• Andexanet alfa (andexanet alfa)
• Apixaban (apixaban)

Snippet

Sponsor: Portola Pharmaceuticals | Conditions: Bleeding | Phase 3 | Status: COMPLETED | Results posted: 2018-09-27